Mackie Research Capital analyst Andre Uddin downgraded Knight Therapeutics (KHTRF) to Hold from Buy with a C$6.50 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
Questions or Comments about the article? Write to editor@tipranks.com